Sarepta Therapeutics Inc
SRPTHealthcare|Biotechnology|USA
$22.07
-0.73 (-3.20%)
Tangible Book
$10.59
Analyst Ratings
| Firm / Analyst | Rating | Price Target | Date |
|---|---|---|---|
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — |
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812"
],
"revenue_estimate": [
1730.17,
1419.07,
1449.01
],
"ebit_estimate": [
315.73,
185.26,
114.77
],
"ebitda_estimate": [
411.3,
109.29,
144.12
],
"net_income_estimate": [
304.31,
144.07,
122.34
],
"per_share_eps_estimate": [
2.85,
1.16,
0.77
],
"eps_nri_estimate": [
3.07,
1.65,
1.23
],
"dividend_estimate": [
null,
null,
null
],
"book_value_per_share_estimate": [
13.89,
15.53,
18.69
],
"pretax_income_estimate": [
359.45,
173.93,
175.06
],
"operating_cash_flow_per_share_estimate": [
3.42,
2.88,
4.24
],
"roa_estimate": [
9.9,
5.2,
1.3
],
"roe_estimate": [
29.74,
12.52,
6.08
],
"gross_margin_estimate": [
78.16,
80.98,
82.4
],
"operating_cash_flow_estimate": [
358.57,
302.3,
444.54
],
"pettm_estimate": [
7.75,
19.12,
28.85
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "-13.49",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": -13.49,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 18.98,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 9.39,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202603",
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
475.59,
436.4,
387.18,
430.27,
386.33,
397.12,
401.58,
409.27
],
"ebit_estimate": [
99.13,
68.54,
43.18,
106.53,
40.58,
73.42,
72.58,
88.56
],
"ebitda_estimate": [
211.57,
58.05,
84.83,
91.35,
null,
null,
null,
null
],
"net_income_estimate": [
65.03,
72.7,
49.07,
101.44,
25.08,
59.77,
53.19,
75.24
],
"per_share_eps_estimate": [
0.68,
0.67,
0.44,
0.84,
0.23,
0.52,
0.49,
0.65
],
"eps_nri_estimate": [
0.98,
0.66,
0.41,
0.75,
0.42,
0.73,
0.69,
0.74
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
79.59,
100.67,
80.73,
130.07,
48.14,
73.11,
75,
90.31
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
40.67,
23.02,
22.21,
16.72,
null,
null,
null,
null
],
"gross_margin_estimate": [
80.5,
84.5,
81,
82.5,
78,
78,
79,
80
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
8.39,
10.11,
10.85,
10.59,
11.65,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "-13.49",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": -13.49,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 18.98,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 9.39,
"future_operating_cash_flow_per_share_estimate_growth": null
}